Adjunctive Garcinia mangostana Linn. (Mangosteen) Pericarp for Schizophrenia: A 24-Week Double-blind, Randomized, Placebo Controlled Efficacy Trial: Pericarpe d'appoint Garcinia mangostana Linn (mangoustan) pour la schizophrenie : un essai d'efficacite de 24 semaines, a double insu, randomise et controle par placebo.

ABSTRACT:

Objectives

Garcinia mangostana Linn. ("mangosteen") pericarp contains bioactive compounds that may target biological pathways implicated in schizophrenia. We conducted a double-blind randomized placebo-controlled trial evaluating the efficacy of adjunctive mangosteen pericarp, compared to placebo, in the treatment of schizophrenia.

Methods

People diagnosed with schizophrenia or schizoaffective disorder (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition), recruited across 2 sites (Brisbane and Victoria, Australia), were randomized to receive 24 weeks of adjunctive mangosteen pericarp (1,000 mg/day) or matched placebo. The primary outcome measure was the Positive and Negative Symptom Scale total score. Secondary outcomes included positive and n

SUBMITTER: Turner A 

PROVIDER: S-EPMC8172349 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature